In settings other than allogeneic stem cell transplantation, sorafenib showed clinical activity in combination with a lower-intensity chemotherapy such as azacitidine (overall response rate (ORR) 46%, complete response (CR) 16%) in patients with FLT3-ITD-positive relapsed or refractory AML [24]. Here, FLT3 is linked to acute myeloid leukemia.